JP2014050390A5 - - Google Patents

Download PDF

Info

Publication number
JP2014050390A5
JP2014050390A5 JP2013209725A JP2013209725A JP2014050390A5 JP 2014050390 A5 JP2014050390 A5 JP 2014050390A5 JP 2013209725 A JP2013209725 A JP 2013209725A JP 2013209725 A JP2013209725 A JP 2013209725A JP 2014050390 A5 JP2014050390 A5 JP 2014050390A5
Authority
JP
Japan
Prior art keywords
cancer
isolated peptide
pharmaceutical composition
residues
pseudomonas aeruginosa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013209725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014050390A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014050390A publication Critical patent/JP2014050390A/ja
Publication of JP2014050390A5 publication Critical patent/JP2014050390A5/ja
Pending legal-status Critical Current

Links

JP2013209725A 2006-09-14 2013-10-04 クプレドキシンによって癌を予防する組成物および方法 Pending JP2014050390A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84435806P 2006-09-14 2006-09-14
US60/844,358 2006-09-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009528468A Division JP2010503409A (ja) 2006-09-14 2007-09-13 クプレドキシンによって癌を予防する組成物および方法

Publications (2)

Publication Number Publication Date
JP2014050390A JP2014050390A (ja) 2014-03-20
JP2014050390A5 true JP2014050390A5 (enExample) 2014-05-01

Family

ID=39184582

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009528468A Withdrawn JP2010503409A (ja) 2006-09-14 2007-09-13 クプレドキシンによって癌を予防する組成物および方法
JP2013209725A Pending JP2014050390A (ja) 2006-09-14 2013-10-04 クプレドキシンによって癌を予防する組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009528468A Withdrawn JP2010503409A (ja) 2006-09-14 2007-09-13 クプレドキシンによって癌を予防する組成物および方法

Country Status (13)

Country Link
EP (1) EP2061498A4 (enExample)
JP (2) JP2010503409A (enExample)
KR (1) KR20090059152A (enExample)
CN (1) CN101595124A (enExample)
AU (1) AU2007296429A1 (enExample)
BR (1) BRPI0714987A2 (enExample)
CA (1) CA2663498A1 (enExample)
IL (1) IL197602A0 (enExample)
MX (1) MX2009002787A (enExample)
NO (1) NO20091267L (enExample)
RU (1) RU2009113812A (enExample)
SG (1) SG174784A1 (enExample)
WO (1) WO2008033987A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US9096663B2 (en) 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US9598470B2 (en) * 2004-10-07 2017-03-21 Craig W. Beattie Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
KR20070108128A (ko) 2004-10-07 2007-11-08 아난다 차크라바르티 쿠프레독신 유래된 수송제 및 이들의 이용 방법
US9968685B2 (en) 2004-10-07 2018-05-15 Brad N. Taylor Methods to treat cancer with cupredoxins
US9434770B2 (en) 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
MX2008000994A (es) 2005-07-19 2008-03-19 Univ Illinois Agentes de transporte para cruzar la barrera hematoencefalica y hacia el interior de las celulas de cancer cerebral, y metodos para el uso de los mismos.
BRPI0718360A2 (pt) 2006-12-04 2013-11-12 Univ Illinois "composições e métodos para o tratamento do câncer com cupredoxinas e dna rico em cpg"
AU2008212788A1 (en) * 2007-02-08 2008-08-14 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
WO2019063097A1 (en) * 2017-09-29 2019-04-04 Oncgnostics Gmbh DETERMINATION OF THE RISK OF NEOPLASIA AND CANCER

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
CN1506375A (zh) * 2002-12-12 2004-06-23 浙江养生堂天然药物研究所有限公司 具有广谱抗肿瘤作用的细菌蛋白天青蛋白及其用途和含有其的药物组合物
KR20070108128A (ko) * 2004-10-07 2007-11-08 아난다 차크라바르티 쿠프레독신 유래된 수송제 및 이들의 이용 방법
BRPI0612424A2 (pt) * 2005-05-20 2009-01-27 Univ Illinois composiÇÕes e mÉtodos para tratar condiÇÕes relacionadas com a sinalizaÇço da efrina com cupredoxinas
KR20080034905A (ko) * 2005-07-19 2008-04-22 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신으로 혈관신생을 제어하는 조성물과 방법

Similar Documents

Publication Publication Date Title
JP2014050390A5 (enExample)
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2013520405A5 (enExample)
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
BR112015009280A2 (pt) preparações liofilizadas de melfalana flufenamida
IL308807B2 (en) Combination therapy for treating cancer
CL2011000124A1 (es) Compuestos derivados de 3-aril-4-heterociclil-pirazoles, inhibidores de proteina quinasa b-raf; metodo de inhibicion in vitro de la proteina quinasa b-raf; composicion farmaceutica; producto de combinacion farmaceutica; y su uso para el tratamiento del cancer.
UA114907C2 (uk) Гетероциклільні сполуки як інгібітори mek
JO3776B1 (ar) التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf
EA201000365A1 (ru) Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза
MD4539B1 (ro) 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1
JP2012176978A5 (enExample)
HRP20170531T1 (hr) Novi terapijski pristupi za liječenje alzheimerove bolesti i povezanih poremećaja putem modulacije angiogeneze
HK1204988A1 (en) Methods and compositions for preventing or treating ophthalmic conditions
RU2012140704A (ru) Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
UA107550C2 (uk) Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів
EA032938B1 (ru) Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
WO2015183995A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
ECSP13012847A (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación.
HRP20151165T1 (hr) Inhibitori apoptoze i njihove uporabe